Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of HK$67.35, indicating an expected upside from the current price of HK$33.25 [2][5]. Core Insights - The company achieved rapid revenue growth in 2024, with revenue reaching RMB 3.02 billion, a year-on-year increase of 30.1%. The net profit was RMB 310 million, reflecting a 21.4% increase, while the adjusted net profit was RMB 400 million, up 31.4% [3][10]. - The company is focusing on overseas expansion through mergers and acquisitions, particularly in regions with significant Chinese populations, such as Singapore, Hong Kong, Malaysia, and Indonesia [4][11]. - The integration of AI technology is expected to enhance operational efficiency and service quality, with plans to launch applications like "Famous Doctor Avatar" and "Health Assistant" in 2025 [12][13]. Financial Performance - Revenue projections for 2025 and 2026 are RMB 3.79 billion and RMB 4.63 billion, respectively, with year-on-year growth rates of 25.3% and 22.2% [5][13]. - The adjusted net profit for 2025 and 2026 is expected to be RMB 480 million and RMB 580 million, with growth rates of 20.6% and 21.0% [5][13]. - The gross profit margin is projected to remain stable at 30.1% over the forecast period [5][13]. Operational Expansion - By the end of 2024, the company operated 79 stores across 20 cities in China and Singapore, with a total of 21 new institutions added during the year [4][11]. - The average selling price (ASP) increased by 3.4% to RMB 559, while the number of patient visits rose by 25.9% to 5.41 million [4][11]. Management and Strategy - The company has developed a standardized operational model that supports its rapid expansion and enhances brand recognition [4][11]. - The management team is leveraging a large dataset of high-quality diagnostic information to develop AI applications, which is expected to replicate high-quality physician resources and improve service delivery [12][13].

Investment Rating - The report maintains an "Outperform" rating for several companies in the food and beverage sector, including Guizhou Moutai, Wuliangye, and Yanjing Beer, among others [1]. Core Insights - The report indicates that five out of eight tracked industries maintained positive growth in March 2025, while three experienced negative growth. The industries with single-digit growth include frozen food, catering, soft drinks, condiments, and beer. In contrast, sub-high-end and above liquor and dairy products saw single-digit declines, with mass liquor experiencing double-digit declines. Overall demand has not significantly increased or decreased, but the decline in liquor and dairy is attributed to cyclical supply surpluses, expected to ease in the latter half of the year [3][31]. Summary by Category Liquor - Sub-high-end and above liquor industry revenue in March was 31 billion yuan, down 6.9% year-on-year. Cumulative revenue for January to March was 130 billion yuan, also down 6.9% year-on-year. Price trends show a general decline in ultra-high-end products, while high-end products have mixed price movements. Inventory levels have slightly increased but remain below last year's figures [4][13]. - Mass liquor revenue in March was 21 billion yuan, down 12.5% year-on-year, with cumulative revenue for the first quarter at 59 billion yuan, down 16.3% year-on-year. This segment has seen 14 consecutive months of negative growth [15]. Beer - The domestic beer industry generated 14.1 billion yuan in revenue in March, a 0.7% year-on-year increase, with cumulative revenue for the first quarter at 46.9 billion yuan, up 0.4% year-on-year. The industry is expected to see slight revenue growth due to stable sales from major breweries [5][17]. Condiments - The condiment industry reported 34.6 billion yuan in revenue for March, a 1.0% year-on-year increase, with cumulative revenue for the first quarter at 119.9 billion yuan, growing 1.7% year-on-year. Compound condiments are outperforming basic condiments, with a trend towards premiumization in consumer products [19]. Dairy Products - The dairy industry revenue in March was 33.5 billion yuan, down 3.5% year-on-year, with cumulative revenue for the first quarter at 121.1 billion yuan, down 2.7% year-on-year. Sales have weakened post-Spring Festival, but channel inventories remain healthy [21]. Frozen Food - The frozen food industry generated 10 billion yuan in revenue in March, a 4.0% year-on-year increase, with cumulative revenue for the first quarter at 38.5 billion yuan, up 4.8% year-on-year. Traditional frozen products are facing demand pressure, but leading companies are expanding channels and product categories [23]. Soft Drinks - The soft drink industry reported 45.6 billion yuan in revenue for March, a 2.2% year-on-year increase, with cumulative revenue for the first quarter at 185.6 billion yuan, up 2.1% year-on-year. Companies are accelerating shipments to capture channel inventory ahead of peak season [25]. Catering - The catering sector's revenue in March was 13.8 billion yuan, a 2.5% year-on-year increase, with cumulative revenue for the first quarter at 43.9 billion yuan, up 3.0% year-on-year. Leading brands are adjusting strategies and expanding store counts, although same-store sales have not shown significant improvement [27].

Investment Rating - The report maintains an "OUTPERFORM" rating for Shanghai Zhonggu Logistics [2][5][14] Core Insights - The company reported FY24 results that exceeded market expectations, with revenue of RMB 11.26 billion, a decrease of 9.5% year-on-year, and a net profit of RMB 1.835 billion, an increase of 6.9% year-on-year. The return on equity (ROE) reached 17.26% [3][12][13] - The company plans to distribute a dividend of RMB 0.79 per share for FY24, resulting in a dividend payout ratio of 90.39% and a dividend yield of 8.3%, indicating strong cash flow and commitment to shareholder returns [5][12][13] - The company is optimistic about domestic and foreign trade prices in 2025, having increased the proportion of its foreign trade business, which has improved revenue per TEU and overall profitability [4][13] Financial Performance Summary - For FY24, the company achieved a total transportation volume of 11.29 million TEUs, a decline of 23.9% year-on-year. Revenue from water transport and land transport was RMB 9.0 billion and RMB 2.24 billion, respectively, with year-on-year changes of -11.0% and -3.7% [4][8] - The overall gross profit margin for FY24 was 15.15%, an increase of 0.9 percentage points year-on-year. Despite a decline in domestic freight rates, the company shifted capacity to the more favorable foreign trade sector, enhancing unit prices and gross margins [4][8] - The report forecasts net profits for FY25, FY26, and FY27 to be RMB 1.966 billion, RMB 2.147 billion, and RMB 2.342 billion, respectively, with corresponding EPS of RMB 0.94, RMB 1.02, and RMB 1.12 [5][14] Valuation and Target Price - The target price is set at RMB 12.17, based on a price-to-earnings (P/E) ratio of 13x for FY25 [2][5][14] - The report highlights the company's strategy of selling ships purchased at lower prices during high market conditions, contributing to significant asset disposal gains [4][13]

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of HK$103.50, indicating an expected relative performance above the market benchmark [2][5]. Core Insights - The company achieved a total of 359,000 cases of invisible orthodontics in 2024, representing a growth of 46.7%. International cases surged to 141,000, up 326.4%, accounting for 39.1% of total cases, while domestic cases grew by 3.2% to 218,000 [3][11]. - Revenue for 2024 reached US$270 million, reflecting a year-on-year increase of 28.2%, with a gross profit margin of 62.6%. The overseas revenue was US$80.5 million, a significant increase of 290.4%, while domestic revenue slightly declined by 0.4% to US$190 million [12][13]. - The company plans to establish a manufacturing facility in Wisconsin, USA, to enhance local operational capabilities, which is expected to reduce geopolitical risks and improve brand recognition among overseas orthodontists [14]. Financial Performance and Forecast - The company forecasts revenues of US$320 million and US$390 million for 2025 and 2026, respectively, with year-on-year growth rates of 19.4% and 20.1%. The net profit attributable to shareholders is expected to be US$12.4 million and US$13.3 million for the same years, reflecting growth of 2.3% and 7.6% [5][15]. - The adjusted net profit for 2024 was US$26.86 million, with a net profit margin of 10.0%. The domestic net profit margin was stable at 19.5%, while overseas losses narrowed slightly to US$29.65 million [13][4].

Investment Rating - The report maintains a "Neutral" rating for S.F. Holding with a target price of RMB 48.50, based on a current price of RMB 43.12 [2][15]. Core Insights - In FY24, S.F. Holding achieved a revenue of RMB 284.42 billion, representing a year-on-year increase of 10.07%, and a net profit of RMB 10.17 billion, which is up 23.51% YoY [3][12]. - The company is transitioning from a traditional "product-selling" model to a "solution-providing" strategy, which is expected to drive sustained growth [15]. Revenue Performance - The total business volume for 2024 reached 13.33 billion parcels, marking an 11.3% increase YoY, with express logistics revenue of RMB 205.8 billion, up 7.7% YoY [4][13]. - International operations outperformed domestic growth, with supply chain and international business revenue increasing by 17.5% YoY to RMB 70.5 billion [4][13]. Cost Management - The company improved its gross margin by 1.1 percentage points to 13.9% in 2024 through enhanced efficiency in transfer, transportation, and delivery processes [5][13]. Shareholder Returns - S.F. Holding increased its dividend payout ratio from 35% to 40% in 2024, distributing a total of RMB 4.10 billion in dividends, along with a one-time special dividend of RMB 4.80 billion [14]. Earnings Forecast - The projected net profit for FY25-27 is RMB 12.10 billion, RMB 14.38 billion, and RMB 16.45 billion, respectively, with corresponding EPS of RMB 2.43, RMB 2.88, and RMB 3.30 [6][15].

Investment Rating - The report assigns a positive investment outlook for Borouge, indicating confidence in its market position and future performance [1]. Core Insights - Borouge is positioned as a global leader in the polyolefins industry, maintaining a strong cost and profit leadership status [1]. - The establishment of Borouge Group International (BGI) is expected to enhance its competitive edge, with a projected EBITDA of over $7 billion throughout the cycle and annual synergies of $500 million [3][4]. - BGI is anticipated to maintain its cost leadership in the global petrochemical cost curve, primarily due to its use of natural gas liquids as feedstock and the economies of scale from its integrated production facilities [3][4]. - The company expects to achieve a price premium for its polyethylene and polypropylene products, with projected premiums of $200/ton and $140/ton, respectively, due to its differentiated Borstar® technology [4]. - BGI's average EBITDA margin is forecasted to reach 26% from FY2020 to FY2024, significantly higher than the industry average of 16% [4]. Company Overview - Borouge is a diversified petrochemical company headquartered in Abu Dhabi, recognized as one of the largest petrochemical producers globally [2]. - The company operates one of the world's largest integrated polyolefins production facilities in Abu Dhabi and has logistics centers across the Middle East, North Africa, Europe, and Asia [2]. - Borouge's primary products consist of polyethylene and polypropylene, with sales concentrated in Europe (39%), Asia (25%), and the Americas (23%) for FY2024 [2]. Strategic Developments - The merger of Borouge and Borealis, along with the acquisition of NOVA Chemicals, will create a new entity, BGI, with a total capacity of 13.6 million tons/year, making it the fourth-largest globally [3]. - The transaction is expected to be completed in Q1 2026, further solidifying Borouge's market position [3]. - Borouge's dividend policy aims to distribute $1.3 billion in dividends for FY2025, with a minimum annual dividend of 16.2 fils per share [6]. Market Outlook - The petrochemical industry is showing early signs of recovery, with Borouge expressing confidence in the sector's strength despite recent challenges [6]. - The company is conducting feasibility studies for a new specialty polyolefins plant in China, reflecting its positive outlook on the Chinese market, which accounts for approximately 30% of its total sales [7].

Investment Rating - The report maintains an "OUTPERFORM" rating for the company with a target price of HK$1.41, based on a current price of HK$1.26 [2][10]. Core Insights - The company reported a profit attributable to shareholders of RMB1.061 billion in 2024, a year-on-year increase of 69.49%, despite a slight decrease in operating revenue of 2.13% to RMB21.265 billion [6][10]. - The company benefits from rising potash fertilizer prices, with potash operating income decreasing from RMB5.250 billion in 2023 to RMB3.939 billion in 2024, accounting for 19% of total revenue [8][10]. - The sales of bio-fertilizers have significantly increased, with revenue share rising from 12% in 2022 to 22% in 2024, and gross profit share increasing from 14% to 36% during the same period [9][10]. Financial Performance - The company’s revenue projections for 2025-2027 are RMB22.693 billion, RMB24.979 billion, and RMB27.292 billion, respectively, with net profits expected to be RMB1.400 billion, RMB1.601 billion, and RMB1.863 billion [5][10]. - The diluted EPS is projected to increase from RMB0.20 in 2025 to RMB0.27 in 2027, reflecting a positive growth trajectory [5][10]. - The company’s gross profit margin is expected to stabilize around 12% to 12.5% over the forecast period [5][10]. Product and Business Segmentation - In 2024, the company sold 7.21 million tons of fertilizers, with compound fertilizers, phosphate fertilizers, and potash fertilizers generating revenues of RMB6.748 billion, RMB6.660 billion, and RMB3.939 billion, respectively [7][10]. - The growth business segment saw a revenue increase of 2.23% year-on-year, while the basic and production business segments experienced declines in segment profit [7][10]. Market Position and Strategy - The company is a key player in China's potash fertilizer market, acting as a negotiator for large import contracts and ensuring domestic supply [8][10]. - The strategic focus on bio-fertilizers aligns with national policies aimed at increasing efficiency and reducing chemical fertilizer usage, enhancing the company's market position [9][10].

[Table_Title] 研究报告 Research Report 31 Mar 2025 日本策略 Japan Strategy 海上观日 Japan Stock Market Weekly Review 美国征收额外关税不是新的新闻，丰田等日本车企因其在美国销售的汽 车中有较大部份是在美国生产的，被很多市场人士认为受关税的负面影 响相对较小。但美国总统特朗普 26 日宣布美国将对所有的进口汽车征 收 25%关税之后，越来越多的人开始担心额外关税不仅会导致进口汽车 部分的利润下降，美国汽车市场整体需求也很可能面临萎缩，不少研究 机构纷纷下调了 25 年美国新车销量预期，这导致汽车股遭到进一步抛 售。 季屏子 Pingzi Ji pz.ji@htisec.com [Table_yemei1] 观点聚焦 Investment Focus [Table_summary] (Please see APPENDIX 1 for English summary) 市场观察： 上周对美国关税政策的担忧左右日本市场，日经 225 指数按周下跌 1.48%收于 37120，TOPIX 指数 按周下跌 1.67%收于 275 ...

Investment Rating - The report maintains an "Outperform" rating for the company [1][2][7] Core Views - The company achieved steady growth in 2024, with revenue of Rmb 3.03 billion (+5.5%) and net profit of Rmb 1.96 billion (+5.3%), maintaining a gross profit margin of 94.6% [3][11] - The company is focusing on overseas mergers and acquisitions, particularly the proposed acquisition of REGEN in South Korea, which is expected to significantly contribute to revenue and profits in 2026 [4][16] Financial Performance - Revenue and profit growth for 2024: Revenue of Rmb 3,026 million, net profit of Rmb 1,958 million, with a gross profit margin of 94.6% [3][11] - Q4 2024 performance showed a revenue decline of 7.0% to Rmb 650 million and a net profit decline of 15.5% to Rmb 370 million [12] - Revenue by product category: Solution-based products Rmb 1.74 billion (+4.4%), Gel-based products Rmb 1.22 billion (+5.0%), Facial implant threads Rmb 6.804 million (+15.0%), Other revenue Rmb 59.192 million (+68.5%) [13][14] Research and Development - Increased R&D investment with a ratio of 10.0% in 2024, focusing on new product pipelines and clinical trials [4][15] - The company has received clinical trial approvals for several new products, indicating a commitment to innovation [15] Acquisition Strategy - The proposed acquisition of REGEN for US$190 million is expected to enhance the company's product offerings and production capacity, with the second factory in South Korea expected to start production in Q2 2025 [4][16] - The target company reported revenue of Rmb 72.23 million and net profit of Rmb 29.5 million from January to September 2024 [16] Earnings Forecast and Valuation - Revenue projections for 2025 and 2026 are Rmb 3.30 billion and Rmb 3.60 billion, respectively, with year-on-year growth of 9.2% and 9.1% [5][17] - The target price is set at Rmb 299.47 per share, corresponding to a P/E ratio of 45x for 2025 and 42x for 2026 [7][17]

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of 5.27 HKD per share based on a 14x PE valuation for 2025E [9]. Core Insights - The company reported total revenue of 21.49 billion RMB for 2024, reflecting a year-on-year increase of 0.2%, and a net profit attributable to shareholders of 861 million RMB, up 3.36% year-on-year. The second half of the year showed significant revenue growth improvement, driven by average price increases despite a decline in sales volume [2][8]. - The gross profit margin increased by 2.61 percentage points to 37.79%, with gross profit rising by 7.65% year-on-year. The sales expense ratio increased due to heightened market competition and promotional spending [2][8]. - The company is focusing on restructuring to enhance customer experience and operational efficiency, with notable performance in the soda and functional drinks categories [2][8]. Financial Data and Forecast - Total revenue projections for 2025-2027 are 23.13 billion RMB, 24.62 billion RMB, and 26.05 billion RMB, respectively. Net profit attributable to shareholders is expected to be 975 million RMB, 1.10 billion RMB, and 1.24 billion RMB for the same years, with corresponding EPS of 0.35 RMB, 0.39 RMB, and 0.44 RMB [2][5][8]. - The company achieved revenue of 16.37 billion RMB in the soda category for 2024, a year-on-year increase of 2.50%, maintaining the leading market share [3][8]. - The juice category reported revenue of 3.13 billion RMB, down 7.46% year-on-year, focusing on profit packaging development [3][8]. Business Strategy and Performance - The company is optimizing its customer structure and marketing network, achieving significant growth in direct sales and maintaining a controllable business revenue ratio of approximately 90% [4][5]. - The smart retail business has shown rapid revenue growth, and the COFCO Enjoy Club has also seen revenue increases with improved average product prices [2][8]. - The company is expanding its product offerings, including new packaging for soda and innovative marketing strategies targeting younger consumers [3][4][8].